Pseudoprogression after glioma therapy: an update

The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression

(2017) Bing Wan et al.   MEDICINE

Advances in neuro-oncology imaging

(2017) Karl-Josef Langen et al.   Nature Reviews Neurology

O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis

(2017) Alexander Heinzel et al.   NEURO-ONCOLOGY

A multi-centre evaluation of eleven clinically feasible brain PET/MRI attenuation correction techniques using a large cohort of patients

(2017) Claes N. Ladefoged et al.   NEUROIMAGE

Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis

(2017) Abdul W. Abbasi et al.   Clinical Neuroradiology

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response

(2016) P. Kickingereder et al.   CLINICAL CANCER RESEARCH

Glioma Recurrence Versus Radiation Necrosis

(2016) Amarnath Jena et al.   CLINICAL NUCLEAR MEDICINE

Intra-lesional spatial correlation of static and dynamic FET-PET parameters with MRI-based cerebral blood volume in patients with untreated glioma

(2016) Jens Göttler et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans

(2016) Philipp Lohmann et al.   EUROPEAN RADIOLOGY

Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas

(2016) Bo Ma et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Amino acid PET for brain tumours — ready for the clinic?

(2016) Karl-Josef Langen et al.   Nature Reviews Neurology

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas

(2016) Nathalie L. Albert et al.   NEURO-ONCOLOGY

MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis

(2016) Praneil Patel et al.   NEURO-ONCOLOGY

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases

(2016) Sied Kebir et al.   NEURO-ONCOLOGY

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET

(2015) S. Kebir et al.   CLINICAL CANCER RESEARCH

Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [18F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience

(2015) Otto M. Henriksen et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Emerging circulating biomarkers in glioblastoma: promises and challenges

(2015) Mehdi Touat et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?

(2015) Isaac Melguizo-Gavilanes et al.   JOURNAL OF NEURO-ONCOLOGY

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

(2015) Hideho Okada et al.   LANCET ONCOLOGY

Prospects of immune checkpoint modulators in the treatment of glioblastoma

(2015) Matthias Preusser et al.   Nature Reviews Neurology

Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma

(2015) Philipp Kickingereder et al.   NEURO-ONCOLOGY

From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?

(2015) Norbert Galldiks et al.   NEURO-ONCOLOGY

Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET

(2014) Norbert Galldiks et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Prognostic Significance of Dynamic 18F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma

(2014) N. L. Jansen et al.   JOURNAL OF NUCLEAR MEDICINE

Comparison of 18F-FET PET and Perfusion-Weighted MR Imaging: A PET/MR Imaging Hybrid Study in Patients with Brain Tumors

(2014) C. P. Filss et al.   JOURNAL OF NUCLEAR MEDICINE

Delayed contrast extravasation MRI: a new paradigm in neuro-oncology

(2014) Leor Zach et al.   NEURO-ONCOLOGY

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pseudoprogression after glioma therapy: a comprehensive review

(2013) Tim J Kruser et al.   Expert Review of Neurotherapeutics

Is There Pseudoprogression in Secondary Glioblastomas?

(2013) Tareq A. Juratli et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The Use of O-(2-18F-Fluoroethyl)-L-Tyrosine PET for Treatment Management of Bevacizumab and Irinotecan in Patients with Recurrent High-Grade Glioma: A Cost-Effectiveness Analysis

(2013) A. Heinzel et al.   JOURNAL OF NUCLEAR MEDICINE

Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients

(2013) N. L. Jansen et al.   JOURNAL OF NUCLEAR MEDICINE

Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients

(2013) K. Herrmann et al.   NEURO-ONCOLOGY

IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy

(2012) Hiroaki Motegi et al.   Brain Tumor Pathology

Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas

(2012) Alexander Heinzel et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Late and Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide

(2012) Moritz Stuplich et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-Effectiveness Analysis of Amino Acid PET-Guided Surgery for Supratentorial High-Grade Gliomas

(2012) A. Heinzel et al.   JOURNAL OF NUCLEAR MEDICINE

Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-L-Tyrosine PET in Comparison to MRI

(2012) N. Galldiks et al.   JOURNAL OF NUCLEAR MEDICINE

Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: Impact on survival

(2012) Laura Negretti et al.   NEURO-ONCOLOGY

Brain Tumors

(2012) Karl Herholz et al.   SEMINARS IN NUCLEAR MEDICINE

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for Glioma Grading

(2011) Maria Lucia Calcagni et al.   CLINICAL NUCLEAR MEDICINE

Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions

(2011) Manmeet S Ahluwalia et al.   Expert Review of Anticancer Therapy

Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma

(2011) Andrea Chassot et al.   JOURNAL OF NEURO-ONCOLOGY

Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma

(2011) R. J. Young et al.   NEUROLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas

(2010) Frederic G Dhermain et al.   LANCET NEUROLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Pseudoprogression and pseudoresponse in the treatment of gliomas

(2009) Dieta Brandsma et al.   CURRENT OPINION IN NEUROLOGY

New advances that enable identification of glioblastoma recurrence

(2009) Isaac Yang et al.   Nature Reviews Clinical Oncology

Distinguishing Glioma Recurrence from Treatment Effect After Radiochemotherapy and Immunotherapy

(2009) Isaac Yang et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Brain Magnetic Resonance Imaging After High-Dose Chemotherapy and Radiotherapy for Childhood Brain Tumors

(2007) Filippo Spreafico et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS